


RxSight Investor Presentation

November 2024



Leading Premium IOLs into the Era of Adjustability


DISCLAIMER & FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight. Such statements may include, without limitation, statements regarding (i) adoption trends and projections regarding the future volume of cataract surgical procedures and related revenue and the role of premium IOLs therein, (ii) estimates of RxSight’s addressable market opportunity and related growth, in the U.S. and globally, (iii) the efficacy of RxSight’s mechanisms and procedures, (iv) clinical comparisons between our and competitors FDA trials; (v) revenue associated with LAL procedures and the premium IOL market, (vi) statements regarding our future financial or business performance, (vii) the timing and success of our development and commercialization of our products, (viii) the ability to receive regulatory approvals and commercialize in selected international markets, (ix) the continued acceptance of our products in the marketplace and (x) our competitive positioning.

This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this presentation from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. We have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source.

More details about these and other risks that may impact RxSight’s business are described under the heading “Risk Factors” in Part II, Item 1A of RxSight’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7, 2024, and in subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. RxSight cautions you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. RxSight does not undertake any duty to update any forward-looking statement to reflect changes in assumptions, the occurrence of unanticipated events or otherwise, or other information in this presentation, except to the extent required by law.

IOL Innovation Over the Past 60 Years



Key Focus for:

Patients



Doctors



Ophthalmic Industry



Growth in WW Number of Implanted IOLs and Manufacturer IOL Revenue

1. Based on raw data provided by Market Scope reports. Data has been processed to express the worldwide number of implanted IOLs and manufacturer IOL revenue as a percent of 1980 levels

Next Phase of IOL Innovation: Fixed Optic IOLs versus Light Adjustable Lens


Fixed Optics IOLs

All other IOLs rely on preoperative measurements to predict patient's needs

Once implanted, the focusing power of the IOL cannot be changed

Light Adjustable Lens

Only LAL allows post-operative optimization of focusing power of the lens



LAL is Transforming the Premium Cataract Surgery Experience

Streamlined patient discussions
pre-operative measurements


Office-based light treatments customize LAL to patient's
optimal refraction using RxSight's Light Delivery Device (LDD)

Choose LAL and
approximate power

Perform
surgery

Real life trial drives LALs
adjustments

Lock-in



Patients experience their vision at home after light
treatment, return to clinic for additional adjustments
or to make the prescription permanent




Adjustability Drives Better Medicine for Patients

Accuracy: measure refraction post-op rather than predict pre-op

Quality: no loss of contrast or increased visual symptoms versus monofocal IOL¹

Customization: Over 90% of subjects had treatable refractive error or changed their refractive target in either eye during light treatments²



~2x the number of eyes with 20/20 vision or better without glasses¹

1. RxSight P160055: FDA Summary of Safety and Effectiveness Data
2. RxSight Data on File: PMCS 006 and PMCS 007

Adjustability Drives Better Business for Doctors & Practices

Enables **more doctors and practices** to participate in premium IOL segment

Allows **more patients** to choose a premium IOL


In RxSight customer survey, **44%** of LAL patients would have received a non-premium IOL¹




1. RxSight 2023 Customer Survey

LAL Adoption Signals Onset of a New Era in Premium IOLs


LDD Installed Base



LAL/LAL+ Units



Total Revenue (in millions)



Momentum Driven by LAL Quality of Vision

888 Installed Base

~1500 Surgeons¹
~420 Optometrists¹




**~165,000 LAL
Implants**

96% Customer
Willingness to
Recommend


93% State the LAL
provides the best
vision

80% Will use LAL in
their own eyes



1. RxSight Data: Clinical Training Certifications Portal

Adjustability Can Spur Expansion of Premium IOL Market



Growth in WW Number of Implanted IOLs and Manufacturer IOL Revenue


1. Based on raw data provided by Market Scope reports. Data has been processed to express the worldwide number of implanted IOLs and manufacturer IOL revenue as a percent of 1980 levels
2. Internal estimate of projected worldwide IOL number and IOL revenue from 2020 to 2040. Assumes 3-4% annual growth in cataract volumes and an increase from ~10% to 20% worldwide premium IOL procedures using 2019 as a baseline

RxSight is Focused on Realizing the Full Potential of Its Unique Technology and Market Opportunity

Expanded Education of Clinicians and Patients

Continued Rapid Platform Development

Staged International Growth



OUS Markets That Make Up >80% of Global Premium IOL Procedures¹

1. Source: MarketScope October 2024 IOL Premium Report


Welcome to the Era of Adjustability

Light Adjustable Lens™

Light Adjustable Lens +™



Empowering Patients To Optimize Their Vision in Ways Meaningful To Them



Thank you